Surrozen, Inc. Common - SRZN STOCK NEWS

Surrozen reported Q3 2024 financial results with significant progress in its clinical programs. The company received a $10 million milestone payment from Boehringer Ingelheim for SZN-413 development. Key highlights include substantial enrollment in the Phase 1b trial of SZN-043 for severe alcohol-associated hepatitis, with proof-of-concept data expected in H1 2025. The first cohort showed no drug-related serious adverse events and potential clinical benefits. The company reported Q3 revenue of $10 million and a net loss of $1.4 million, with cash position at $31 million as of September 30, 2024.

Surrozen (SRZN) has announced a strategic research collaboration with TCGFB to develop antibody therapeutics targeting TGF-β for treating idiopathic pulmonary fibrosis (IPF). Under the two-year agreement, Surrozen will provide antibody discovery services while TCGFB will retain all TGF-β product-related intellectual property. In compensation, TCGFB will pay Surrozen up to $6 million plus third-party costs and issue a warrant for up to 3,380,000 shares of TCGFB common stock at $0.0001 per share, subject to vesting conditions.

Surrozen (Nasdaq: SRZN) has announced a $10 million milestone payment from Boehringer Ingelheim as part of their collaboration on retinal diseases. Boehringer is advancing the development of SZN-413, a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wnt signaling, designed using Surrozen's SWAP™ technology.

SZN-413 offers the potential to restore retinal function in patients with retinal vascular diseases, which affect nearly 150 million people globally. Preclinical data suggest that SZN-413 could stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage.

Craig Parker, President and CEO of Surrozen, expressed excitement about Boehringer's decision to proceed with SZN-413's development, highlighting the strong evidence supporting Fzd-4 specific Wnt signaling's role in retinal vasculature.

Surrozen (Nasdaq: SRZN) reported Q2 2024 financial results and business updates. Key highlights include:

• Ongoing enrollment in SZN-043 Phase 1b trial for Severe Alcoholic Hepatitis
• Presented first-in-human data from SZN-043 Phase 1a trial at EASL
• Published study on Targeted Protein Degradation technologies
• Cash position: $37.8 million as of June 30, 2024
• R&D expenses: $5.3 million, down from $6.9 million in Q2 2023
• Net loss: $25.3 million, up from $9.4 million in Q2 2023

The company anticipates proof-of-concept data from the SZN-043 Phase 1b trial in H1 2025 and potential nomination of a lead Fzd-4 targeted Wnt agonist development candidate in 2024, which could trigger a $10 million milestone payment from Boehringer Ingelheim.

Surrozen (Nasdaq: SRZN) has published new data in eLife demonstrating the potential of its proprietary SWEETS platform to enhance Wnt signaling. The study highlights the development of two new ASGR-targeted SWEETS bispecific antibodies that improve Wnt-signal activation through a unique protein degradation platform. This innovation offers promising new avenues for treating liver diseases by promoting cell-specific regenerative therapeutics. Additionally, Surrozen released a review in iScience detailing advancements in Wnt-activating technologies, underscoring the significant progress in the field and its potential to address various tissue degenerative diseases.

Surrozen presented preliminary Phase 1a study results of their novel drug SZN-043 at the 2024 European Association for the Study of the Liver (EASL) conference in Milan. This study involved 40 healthy volunteers and 8 liver cirrhosis patients, focusing on dose safety and tolerance. SZN-043 showed potential in increasing Wnt signaling and hepatocyte proliferation, with pharmacodynamic biomarkers confirming target engagement. Mild, transient serum transaminase elevations were noted but resolved without intervention. Current enrollment is ongoing for a Phase 1b study targeting severe alcohol-associated hepatitis, aiming to optimize Wnt pathway modulation for liver regeneration.

Surrozen has dosed its first patient in a Phase 1b clinical trial for SZN-043, a bispecific fusion protein targeting ASGR1, aimed at treating severe alcohol-associated hepatitis. This open-label, multi-center trial will involve around 30 patients and assess safety, pharmacokinetics, immunogenicity, and efficacy endpoints like MELD and Lille scores, which are linked to clinical improvement and survival.

CEO Craig Parker highlighted the company's progress and expects proof-of-concept data by the first half of 2025. Previous Phase 1a data indicated SZN-043's safety, tolerability, and beneficial effects on liver function. The trial addresses a significant unmet need, as severe alcohol-associated hepatitis has had no survival improvements for over 50 years.

Surrozen presented data at the ARVO Annual Meeting showcasing the potential of their antibody-based Wnt mimetic technologies in treating cornea endothelial dystrophies and Dry Eye Disease. The preclinical studies demonstrated significant improvements in corneal edema, endothelial cell proliferation, and tear volume production utilizing Surrozen's SWAP technologies. These findings offer hope for patients suffering from these severe eye diseases.

Surrozen, Inc. provided its first quarter 2024 financial results and business updates, focusing on advancing the SZN-043 Phase 1b trial for severe alcohol-associated hepatitis. The company presented promising preclinical data for eye and lung diseases, and highlighted a partnership with Boehringer Ingelheim for retinal disease treatment. Financially, while cash and cash equivalents decreased, a recent financing round boosted proforma cash. Research and development expenses decreased, along with general and administrative expenses, showcasing a strategic focus on clinical programs.